FDA Approves Shionogi's XOCOVA as First Oral COVID-19 Prevention Treatment
Event summary
- FDA approved Shionogi's XOCOVA (ensitrelvir) for post-exposure prophylaxis of COVID-19 in adults and adolescents 12+.
- XOCOVA reduced symptomatic COVID-19 risk by 67% in Phase 3 trial SCORPIO-PEP.
- Approval came ahead of the June 16, 2026 PDUFA action date.
- XOCOVA is a 5-day oral regimen with 3 tablets on day one and 1 tablet on days two through five.
- The drug is the first and only oral option for preventing COVID-19 after exposure.
The big picture
Shionogi's FDA approval of XOCOVA fills a critical gap in COVID-19 prevention, offering the first oral option for post-exposure prophylaxis. This approval comes as COVID-19 remains a significant public health concern, with ongoing transmission and severe outcomes, particularly in vulnerable populations. The drug's success in reducing symptomatic cases by 67% positions it as a key tool in managing the pandemic's long-term impact. The approval also underscores Shionogi's strategic focus on antiviral innovations, building on its portfolio in infectious diseases.
What we're watching
- Market Adoption
- How quickly XOCOVA will be adopted in household and institutional settings, particularly in nursing homes and acute care facilities.
- Competitive Positioning
- Whether Shionogi can maintain XOCOVA's first-mover advantage in the post-exposure prophylaxis market.
- Regulatory Dynamics
- The pace at which other regulatory agencies approve XOCOVA for similar indications globally.
Related topics